In GBM cells, sortilin promotes invasion and mesenchymal transition through a mechanism involving a GSK-3β/β-catenin/twist pathway [14] and presenilin1 [15], but the relevance of sortilin as a clinical biomarker or a therapeutic target is unclear. Here, SORT1 is linked to glioblastoma.